Novo Nordisk (NVO) slides as investors refocus on ongoing GLP-1 pricing pressure and softer 2026 outlook

Novo Nordisk (NVO) is down 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks consistent with a pullback after recent strength, with investors continuing to weigh the company’s softer 2026 outlook against intensifying GLP-1 competition and ongoing pricing actions. With no single, company-specific shock apparent today, the decline may largely reflect sentiment resetting toward margin and growth concerns in obesity and diabetes drugs.

Details:

Novo Nordisk has pointed investors to significant pricing and competitive pressures across GLP-1 therapies, which has kept the stock highly sensitive to any signs of weaker net pricing or slower growth.

The company has announced a lower U.S. list price level for Wegovy, Ozempic, and Rybelsus effective January 1, 2027, reinforcing the market narrative that price normalization is becoming a bigger part of the category.

Novo has also been testing alternative pricing approaches for Wegovy in the U.S., including subscription-style structures aimed at self-pay channels, which could support access but may pressure near-term realized pricing.

Novo published an April 28, 2026 update highlighting upcoming clinical and real-world data presentations at a major obesity congress in mid-May, which can keep trading focused on near-term catalysts and positioning.

Sources:

Novo Nordisk (IR/press release), Mercer, Axios

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive NVO Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NVO Hedge Fund Activity

We have seen 548 institutional investors add shares of $NVO stock to their portfolio, and 808 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS removed 6,502,318 shares (-36.7%) from their portfolio in Q4 2025, for an estimated $330,837,939
PRICE T ROWE ASSOCIATES INC /MD/ added 4,836,285 shares (+99.7%) to their portfolio in Q4 2025, for an estimated $246,070,180
VOLORIDGE INVESTMENT MANAGEMENT, LLC added 4,302,126 shares (+851.6%) to their portfolio in Q4 2025, for an estimated $218,892,170
CITADEL ADVISORS LLC added 4,278,889 shares (+136.6%) to their portfolio in Q4 2025, for an estimated $217,709,872
FMR LLC removed 4,058,066 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $206,474,398
FAYEZ SAROFIM & CO removed 3,118,838 shares (-42.4%) from their portfolio in Q4 2025, for an estimated $158,686,477
DAVENPORT & CO LLC removed 2,122,035 shares (-96.2%) from their portfolio in Q1 2026, for an estimated $76,085,564

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$NVO Congressional Stock Trading

Members of Congress have traded $NVO stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.

$NVO Analyst Ratings

Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Goldman Sachs issued a "Buy" rating on 11/28/2025

To track analyst ratings and price targets for $NVO, check out Quiver Quantitative's $NVO forecast page.

$NVO Price Targets

Multiple analysts have issued price targets for $NVO recently. We have seen 3 analysts offer price targets for $NVO in the last 6 months, with a median target of $46.0.

Here are some recent targets:

James Quigley from Goldman Sachs set a target price of $41.0 on 03/02/2026
An analyst from CICC set a target price of $73.5 on 01/09/2026
Evan David Seigerman from BMO Capital set a target price of $46.0 on 11/25/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.